Video

Stephen Krieger: Determining Best Treatments in Multiple Sclerosis

Author(s):

While having a number of choices to pick from when treating patients with multiple sclerosis can be advantageous there can also be challenges that need to be addressed by both doctors and patients

While having a number of choices to pick from when treating patients with multiple sclerosis can be advantageous there can also be challenges that need to be addressed by both doctors and patients

Speaking at the annual meeting of the American Academy of Neurology in Vancouver, Stephen Krieger, MD, Mount Sinai Hospital, said there is emerging data that could show a reverse of some of the damages of MS. Learning about clinical trials, and being there with a patient who is treated for the first time, Krieger said, is meaningful. “We could try things and be in studies that will benefit the patient, but it also benefits science,” he said.

He said there is a lot of interest in MS. “There are certainly more of us now than years ago, and that gives patients more opportunities to have MS-familiar doctors.”

Kreiger added with the broad aspects of MS could mean broad choices in treatment strategies. “I think we are going to see combined treatments of MS,” Krieger said. "I think it is going to get more complicated and more personalized."

Related Videos
Christian Sadaka, MD: Significant Increase in Pediatric Gastroparesis Hospital Admissions After COVID-19
Developing Risk Assessment Tools for Viruses in School
Getting Black Men Involved in Their Health Care, Clinical Research
Patient Involvement in Advanced HF Treatment, with Ashley Malliett, DMSc, MPAS, PA-C
Aaron Henry, PA-C, MSHS: Regaining Black Male Patient Trust in the Doctor's Office
How to Adequately Screen for and Treat Cognitive Decline in Primary Care
James R. Kilgore, DMSc, PhD, PA-C: Cognitive Decline Diagnostics
What Should the American Academy of Physician Associates Focus on in 2025?
Danielle O'Laughlin, PA-C, MS: Navigating Long-Term Risks, Family Planning in PCOS
© 2024 MJH Life Sciences

All rights reserved.